From: "Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer
Lines of Endocrine therapy
2 nd line
3 rd line
4 th line
N
68
23
5
N of CB (%)
47 (69.1)
10 (43.5)
1(20.0)
Median DOR with CB (months)
12.0+(7–81)
11.0 (8–32)
15.0
N still receiving treatment
17
0